To include your compound in the COVID-19 Resource Center, submit it here.

FDA reviewers back extrapolation for Amgen's biosimilar Humira

FDA reviewers concluded the "totality of the evidence" support the biosimilarity of ABP 501 from Amgen Inc. (NASDAQ:AMGN) to Humira adalimumab from AbbVie Inc. (NYSE:ABBV), its U.S.-licensed reference product. In briefing documents released ahead of

Read the full 352 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE